Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Pallett, Scott J CRayment, Michael
Heskin, Joseph
Mazzella, Andrea
Jones, Rachael
Mughal, Nabeela
Randell, Paul
Davies, Gary W
Moore, Luke S P
Publication date
2022-08-12Subject
Communicable diseases
Metadata
Show full item recordAbstract
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.Citation
Pallett SJC, Rayment M, Heskin J, Mazzella A, Jones R, Mughal N, Randell P, Davies GW, Moore LSP. Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. Diagn Microbiol Infect Dis. 2022 Nov;104(3):115788. doi: 10.1016/j.diagmicrobio.2022.115788. Epub 2022 Aug 12Type
ArticleAdditional Links
https://www.sciencedirect.com/journal/diagnostic-microbiology-and-infectious-diseasePMID
36084423Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.diagmicrobio.2022.115788